Clinical Trials
155 trialsMeasuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
ESTHER
Dartmouth-Hitchcock Medical Center
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
ToPCourT
Wake Forest University Health Sciences
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
ASPEN-09-03
ALX Oncology Inc.
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
H3RAKLES
Institut Curie
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
ELEMENT
GBG Forschungs GmbH
Triple-B
The Netherlands Cancer Institute
PAVO
Tempus AI
AGADIR
Institut Bergonié
ALTER
UNICANCER
METALLICA
MedSIR
DESTINY-Breast01
Daiichi Sankyo
DEBBRAH
MedSIR
MERIBEL
MedSIR
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Definitive Radiation for High-Risk Spine Metastases
Stony Brook University
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
PAKT
Queen Mary University of London
MIMOSA
The Netherlands Cancer Institute
QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
NantCell, Inc.
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
POLLY
Dartmouth-Hitchcock Medical Center
PELICAN
Queen Mary University of London
PYTHIA
ETOP IBCSG Partners Foundation
METEORA-II
ETOP IBCSG Partners Foundation
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Fudan University
LODESTAR
pharmaand GmbH
OASIS
Georgetown University
HER2-Signal
Massachusetts General Hospital
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
OncoSec Medical Incorporated
INGE-B
iOMEDICO AG
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
Universitaire Ziekenhuizen KU Leuven
DORA
Duke University
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
MULAN
Fudan University
GELATO
The Netherlands Cancer Institute
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Fudan University
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
Medstar Health Research Institute
DETECT
Shanghai Jiao Tong University School of Medicine
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
TONIC
The Netherlands Cancer Institute
TONIC-2
The Netherlands Cancer Institute